Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Combe

Showing results (91-100 of 282) with videos related to

Pageof 29
Sort By:
Rheumatology (Oxford, England)|October 29, 2014
Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureFrank Behrens, Juan D Cañete, Ignazio Olivieri, et al.
The Journal of Rheumatology|May 18, 2010
Tumor necrosis factor-alpha blockers in SAPHO syndromeKaouther Ben Abdelghani, Delphine Gerard Dran, Jacques-Eric Gottenberg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activityClaire I Daien, Sarah Gailhac, Thibault Mura, et al.
Rheumatology (Oxford, England)|September 19, 2014
High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritisClaire Immediato Daïen, Sarah Gailhac, Rachel Audo, et al.
Arthritis Research & Therapy|November 16, 2019
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohortCédric Lukas, Julia Mary, Michel Debandt, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE RegistryCédric Lukas, Manon Redondin, Isabelle Pane, et al.
Joint Bone Spine|August 7, 2020
Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIRJoanna Kedra, Benjamin Granger, Stéphanie Emilie, et al.
Arthritis Research & Therapy|July 30, 2015
Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohortRachel Audo, Claire Daien, Laura Papon, et al.
Rheumatology (Oxford, England)|December 15, 2020
Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritisCamille Roubille, Amandine Coffy, Nathalie Rincheval, et al.
Rheumatology (Oxford, England)|July 19, 2013
GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimateIsabel Castrejón, Theodore Pincus, Martin Soubrier, et al.
Pageof 29

Showing results (91-100 of 282) with videos related to

Sort By:
Pageof 29
Rheumatology (Oxford, England)|October 29, 2014
Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureFrank Behrens, Juan D Cañete, Ignazio Olivieri, et al.
The Journal of Rheumatology|May 18, 2010
Tumor necrosis factor-alpha blockers in SAPHO syndromeKaouther Ben Abdelghani, Delphine Gerard Dran, Jacques-Eric Gottenberg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activityClaire I Daien, Sarah Gailhac, Thibault Mura, et al.
Rheumatology (Oxford, England)|September 19, 2014
High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritisClaire Immediato Daïen, Sarah Gailhac, Rachel Audo, et al.
Arthritis Research & Therapy|November 16, 2019
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohortCédric Lukas, Julia Mary, Michel Debandt, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE RegistryCédric Lukas, Manon Redondin, Isabelle Pane, et al.
Joint Bone Spine|August 7, 2020
Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIRJoanna Kedra, Benjamin Granger, Stéphanie Emilie, et al.
Arthritis Research & Therapy|July 30, 2015
Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohortRachel Audo, Claire Daien, Laura Papon, et al.
Rheumatology (Oxford, England)|December 15, 2020
Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritisCamille Roubille, Amandine Coffy, Nathalie Rincheval, et al.
Rheumatology (Oxford, England)|July 19, 2013
GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimateIsabel Castrejón, Theodore Pincus, Martin Soubrier, et al.
Pageof 29